As a GTC shareholder, I like the Teva-CoGenesys deal insofar as it establishes another price benchmark for this kind of acquisition. The $400M price tag is identical to what MRK paid for GlycoFi in 2006 (#msg-11018747).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.